DK1606318T3 - Forbedrede Fc-fusionsproteiner - Google Patents

Forbedrede Fc-fusionsproteiner

Info

Publication number
DK1606318T3
DK1606318T3 DK04723552T DK04723552T DK1606318T3 DK 1606318 T3 DK1606318 T3 DK 1606318T3 DK 04723552 T DK04723552 T DK 04723552T DK 04723552 T DK04723552 T DK 04723552T DK 1606318 T3 DK1606318 T3 DK 1606318T3
Authority
DK
Denmark
Prior art keywords
domain
fusion proteins
enhanced
ligand
receptor
Prior art date
Application number
DK04723552T
Other languages
English (en)
Inventor
Henning Walczak
Original Assignee
Apogenix Gmbh
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh, Deutsches Krebsforsch filed Critical Apogenix Gmbh
Application granted granted Critical
Publication of DK1606318T3 publication Critical patent/DK1606318T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
DK04723552T 2003-03-26 2004-03-26 Forbedrede Fc-fusionsproteiner DK1606318T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03006949 2003-03-26
PCT/EP2004/003239 WO2004085478A2 (en) 2003-03-26 2004-03-26 Improved fc fusion proteins

Publications (1)

Publication Number Publication Date
DK1606318T3 true DK1606318T3 (da) 2009-11-02

Family

ID=33040920

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04723552T DK1606318T3 (da) 2003-03-26 2004-03-26 Forbedrede Fc-fusionsproteiner

Country Status (15)

Country Link
US (2) US8007813B2 (da)
EP (2) EP1606319A2 (da)
JP (2) JP4741464B2 (da)
AT (1) ATE438662T1 (da)
AU (2) AU2004224122A1 (da)
CA (2) CA2520138C (da)
CY (1) CY1109536T1 (da)
DE (1) DE602004022390D1 (da)
DK (1) DK1606318T3 (da)
ES (1) ES2327409T3 (da)
HK (1) HK1077592A1 (da)
PL (1) PL1606318T3 (da)
PT (1) PT1606318E (da)
SI (1) SI1606318T1 (da)
WO (2) WO2004085479A2 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
DK2229956T3 (da) 2004-09-13 2013-07-29 Genzyme Corp Multimere konstruktioner
KR102073629B1 (ko) * 2005-02-03 2020-02-05 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
AU2006279541A1 (en) * 2005-08-15 2007-02-22 The Regents Of The University Of California VEGF-activated FAS ligands
US10155816B2 (en) * 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2634080A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
CN101400703B (zh) 2006-02-01 2013-05-08 赛法隆澳大利亚控股有限公司 结构域抗体构建体
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
WO2007131654A2 (de) * 2006-05-17 2007-11-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antientzündliches fusionsprotein
ES2523992T3 (es) 2006-12-28 2014-12-03 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo
CN101835802B (zh) 2007-06-01 2014-04-09 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
EP2540740B1 (en) 2008-06-17 2014-09-10 Apogenix GmbH Multimeric TNF receptors
US20110189194A1 (en) * 2008-07-14 2011-08-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
EP2536747B1 (en) * 2010-02-19 2017-09-27 Université de Liège A polynucleotide for use in treatment of influenza a virus induced diseases, encoding modified mx protein, said modified mx protein, and a transgenic animal expressing gene encoding modified mx protein
WO2012016073A2 (en) 2010-07-28 2012-02-02 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
PL2601214T3 (pl) 2010-08-06 2018-05-30 Genzyme Corporation Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
WO2014001325A1 (en) * 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
RU2652348C2 (ru) 2012-07-18 2018-04-25 Аподжиникс Аг Ингибиторы сигнального пути cd95 для лечения мдс
CN109897115A (zh) * 2012-07-18 2019-06-18 阿珀吉尼科斯股份公司 包含CD95-Fc同种型的混合物的组合物
JP2015527366A (ja) 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子
US10189887B2 (en) 2014-04-17 2019-01-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polypeptides and uses thereof for reducing CD95-mediated cell motility
WO2016118577A1 (en) * 2015-01-22 2016-07-28 Medimmune, Llc Thymosin-beta-four fusion proteins
WO2016177771A1 (en) 2015-05-04 2016-11-10 Apogenix Ag Single-chain cd40-receptor agonist proteins
LT3325011T (lt) 2015-07-24 2021-01-25 Gliknik Inc. Iš žmogaus baltymo fragmentų sulieti baltymai, siekiant sukurti tvarkingai multimerizuoto imunoglobulino fc kompozicijas su padidintu komplemento surišimu
CN108430492B (zh) 2015-10-23 2022-05-03 阿珀吉科吉尼科斯股份公司 单链cd27受体激动剂蛋白
AU2016342420B2 (en) 2015-10-23 2020-10-01 Apogenix Ag Single-chain LIGHT receptor agonist proteins
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
CN110177802A (zh) 2016-12-09 2019-08-27 格利克尼克股份有限公司 多聚化stradomer GL-2045的制造优化
CA3043251A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
CA3162703A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
JP7817937B2 (ja) 2020-02-27 2026-02-19 ターンストーン バイオロジクス コーポレイション 腫瘍反応性ｔ細胞のエクスビボ富化および増大のための方法ならびに関連するその組成物
GB202016058D0 (en) 2020-10-09 2020-11-25 Ucl Business Ltd Therapeautic treatment
CN115197328B (zh) * 2021-04-09 2025-05-16 北京大学第一医院 一种可清除体内免疫球蛋白A的重组融合蛋白酶及其制备方法和在治疗IgA肾病中的应用
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
DE4447484C2 (de) 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6306395B1 (en) 1996-05-02 2001-10-23 Mochida Pharmaceutical Co., Ltd. Fas antigen derivatives
CA2270423C (en) 1996-10-31 2009-09-15 Mochida Pharmaceutical Co., Ltd. Prophylactic/therapeutic agent
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
DK1273304T4 (da) 1997-02-21 2009-08-31 Amgen Inc Anvendelse af interleukin-15
AU8784498A (en) * 1997-08-15 1999-03-08 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
TR200002824T2 (tr) 1998-03-30 2000-12-21 Eli Lilly And Company TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları.
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2000066156A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
DE19959049A1 (de) 1999-12-07 2001-06-28 Deutsches Krebsforsch Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US7189830B2 (en) * 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DE10122140A1 (de) 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Rekombinante Fusionsproteine und deren Trimere
MXPA03010747A (es) * 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
DE10160248A1 (de) 2001-12-07 2003-06-26 Alexander Cherkasky Fusionsproteinen enthaltend Fc-Regionen

Also Published As

Publication number Publication date
ES2327409T3 (es) 2009-10-29
EP1606319A2 (en) 2005-12-21
WO2004085479A3 (en) 2004-11-25
SI1606318T1 (sl) 2009-12-31
CA2520138C (en) 2017-05-23
JP2007524365A (ja) 2007-08-30
US20110305697A1 (en) 2011-12-15
JP2007533595A (ja) 2007-11-22
CY1109536T1 (el) 2014-08-13
PT1606318E (pt) 2009-11-10
US20070269449A1 (en) 2007-11-22
US8007813B2 (en) 2011-08-30
DE602004022390D1 (de) 2009-09-17
EP1606318A2 (en) 2005-12-21
AU2004224122A1 (en) 2004-10-07
WO2004085479A2 (en) 2004-10-07
JP4741464B2 (ja) 2011-08-03
AU2004224123A1 (en) 2004-10-07
WO2004085478A3 (en) 2005-01-06
ATE438662T1 (de) 2009-08-15
EP1606318B1 (en) 2009-08-05
PL1606318T3 (pl) 2010-01-29
CA2520138A1 (en) 2004-10-07
WO2004085478A2 (en) 2004-10-07
HK1077592A1 (zh) 2006-02-17
CA2520254A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
DK1606318T3 (da) Forbedrede Fc-fusionsproteiner
CY1112787T1 (el) Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
ECSP067073A (es) Anticuerpos anti-il-13 y complejos
DK1047781T3 (da) IL-18-receptorer
ATE490969T1 (de) Modifizierte transferrin-fusionsproteine
ATE482719T1 (de) Behandlungsverfahren unter verwendung von anti- cd22-antikörpern
SE0401601D0 (sv) Protofibril specific antibodies and uses thereof
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
ES2333598T5 (es) Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
DE60333306D1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
ES2187954T3 (es) Anticuerpos anti-integrina avb3 antagonistas.
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
CY1110843T1 (el) Αντισωματα εναντι il-22ra και εταιροι δεσμευσης και μεθοδοι χρησης σε φλεγμονη
DK1355919T3 (da) Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
NO20005637L (no) Hybridprotein for å inhibere degranulasjon av mastocyter og anvendelsen derav
ATE484749T1 (de) Von anti-trichinella-antikörpern erkannte polypeptide und ihre verwendung
DE50309342D1 (de) Gemisch mindestens zweier fusionsproteine sowie ihre herstellung und verwendung
DE602006018424D1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper
DK1539221T3 (da) Transferrin-fusionsproteinbiblioteker
DK1398325T3 (da) Monoklonalt antistof, specifikt for en epitop af inaktiveret felint immundeficiens-kodet glykoprotein
ATE466076T1 (de) Gewebe transglutaminase
EP1805209A4 (en) NOGO-A POLYPEPTIDE FRAGMENTS, VARIANT OF NOGO RECEPTOR-1 POLYPEPTIDES AND USE
ATE490274T1 (de) Verwendungen des monoklonalen antikörpers 8h9